Persistent Long-Term Changes In Lymphocyte Subsets Induced By Polyclonal Antibodies1
- 1 November 1997
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 64 (10) , 1432-1437
- https://doi.org/10.1097/00007890-199711270-00010
Abstract
Clinicians are well aware of the short-term effects of immunosuppression by mono- or polyclonal antibodies. Little is known about long-term changes induced by these therapies. Forty-three renal allograft recipients were selected according to their initial postoperative immunosuppression: (1) BI group=basic immunosuppression with steroids and cyclosporine, n=16; (2) ATG group=basic immunosuppression plus polyclonal antibody antithymocyte globulin (ATG), n=11; and (3) OKT3 group=basic immunosuppression plus monoclonal antibody OKT3, n=16 patients. At intervals of 6 months, the following parameters were measured prospectively: lymphocyte surface antigens (HLA-DR, CD3, CD4, CD8, CD16, CD19, CD56, and CD57); serum and urine neopterin; serum amyloid A; and indirect and direct tests for herpes viruses. The mean period of observation was 58.4 months. The most significant differences between the groups occurred for CD4+ and CD8+ T cells. The ratios of CD4+ to CD8+ cells (n=278 measurements) were significantly and persistently lower in the ATG group (P<0.001, Brown-Mood test). Five years after transplantation, the ATG group had a CD4+ to CD8+ cell ratio of x=0.6 versus x=1.7 in the OKT3 group and x=2.0 in the BI group. This inversion was due to a persistent depletion of the CD4+ cells and an increased regeneration of the CD8+ cells, in particular of the CD8+brightCD57+ subpopulation. Extent and duration of CD4+ depletion correlated with the cumulative ATG dose (r=0.7, P<0.05, Spearman rank correlation test). Therapy with polyclonal antibody ATG induces dose-dependent long-term changes in T-cell lymphocyte subsets, which persist over a period of years.Keywords
This publication has 29 references indexed in Scilit:
- Intraoperative T-Cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantationTransplantation Proceedings, 1997
- Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practiceEuropean Journal of Clinical Investigation, 1996
- Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant RecipientsAnnals of Internal Medicine, 1995
- RANDOMIZED CLINICAL TRIAL OF ANTITHYMOCYTE GLOBULIN INDUCTION IN RENAL TRANSPLANTATION COMPARING A FIXED DAILY DOSE WITH DOSE ADJUSTMENT ACCORDING TO T CELL MONITORINGTransplantation, 1995
- A RANDOMIZED PROSPECTIVE TRIAL OF PROPHYLACTIC IMMUNOSUPPRESSION WITH ATG-FRESENIUS VERSUS OKT3 AFTER RENAL TRANSPLANTATIONTransplantation, 1995
- Treatment of refractory rheumatoid arthritis with a chimeric ANTI‐CD4 monoclonal antibodyArthritis & Rheumatism, 1994
- SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2Transplantation, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Long‐term immunomodulatory effects of t lymphocyte depletion in patients with systemic sclerosisArthritis & Rheumatism, 1990
- The Human Immune Response to the OKT3 Monoclonal Antibody Is OligoclonalScience, 1986